Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M640Revenue $M31.3Net Margin (%)-781.0Z-Score-4.7
Enterprise Value $M745EPS $-1.3Operating Margin %-640.5F-Score2
P/E(ttm))0Cash Flow Per Share $0.7Pre-tax Margin (%)-781.3Higher ROA y-yY
Price/Book9.310-y EBITDA Growth Rate %0Quick Ratio4.8Cash flow > EarningsY
Price/Sales19.35-y EBITDA Growth Rate %0Current Ratio5.0Lower Leverage y-yN
Price/Cash Flow6.3y-y EBITDA Growth Rate %0ROA % (ttm)-48.6Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-369.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M184ROI % (ttm)-57.3Gross Margin Increase y-yN

Gurus Latest Trades with EXEL

Number of guru portfolios checked: 54.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
EXELJohn Burbank 2013-03-31 Sold Out -0.0019%$4.41 - $5.03
($4.69)
$ 3.29-30%Sold Out0
EXELJohn Burbank 2012-12-31 Buy $4.33 - $5.32
($4.79)
$ 3.29-31%New holding, 10753 sh.10,753
EXELJean-Marie Eveillard 2012-09-30 Add0.02%$4.28 - $6.45
($5.29)
$ 3.29-38%Add 422.58%1,175,800
EXELJean-Marie Eveillard 2012-03-31 Add$4.49 - $6.47
($5.14)
$ 3.29-36%Add 125%225,000
EXELJean-Marie Eveillard 2011-12-31 Buy $3.95 - $7.81
($5.01)
$ 3.29-34%New holding, 100000 sh.100,000
EXELCarl Icahn 2011-09-30 Sold Out -0.43%$5.5 - $9.22
($7.34)
$ 3.29-55%Sold Out0
EXELJean-Marie Eveillard 2011-03-31 Sold Out $7.22 - $12.45
($9.89)
$ 3.29-67%Sold Out0
EXELJean-Marie Eveillard 2010-12-31 Buy 0.01%$3.98 - $9.08
($5.66)
$ 3.29-42%New holding, 280000 sh.280,000
EXELJean-Marie Eveillard 2009-12-31 Sold Out -0.02%$5.33 - $8
($6.86)
$ 3.29-52%Sold Out0
EXELJean-Marie Eveillard 2009-09-30 Buy 0.02%$4.4 - $6.99
($5.65)
$ 3.29-42%New holding, 274700 sh.274,700
EXELJean-Marie Eveillard 2009-06-30 Sold Out -0.01%$4.16 - $5.55
($4.88)
$ 3.29-33%Sold Out0
EXELJean-Marie Eveillard 2009-03-31 Reduce$4.32 - $5.85
($4.8)
$ 3.29-32%Reduce -25.67%144,800
EXELCarl Icahn 2008-12-31 Add0.19%$2.4 - $5.12
($3.8)
$ 3.29-13%Add 80.31%2,357,110
EXELJean-Marie Eveillard 2008-12-31 Add$2.4 - $5.12
($3.8)
$ 3.29-13%Add 25.84%194,800
EXELCarl Icahn 2008-09-30 Buy 0.18%$4.8 - $7.12
($6.1)
$ 3.29-46%New holding, 1307280 sh.1,307,280
EXELJean-Marie Eveillard 2008-09-30 Reduce$4.8 - $7.12
($6.1)
$ 3.29-46%Reduce -44.12%154,800
EXELJean-Marie Eveillard 2008-06-30 Add0.01%$5.07 - $7.93
($6.7)
$ 3.29-51%Add 151.82%277,000
EXELGeorge Soros 2008-06-30 Sold Out $5.07 - $7.93
($6.7)
$ 3.29-51%Sold Out0
EXELJean-Marie Eveillard 2008-03-31 Add$5.79 - $8.32
($6.8)
$ 3.29-52%Add 37.5%110,000
EXELGeorge Soros 2008-03-31 Buy $5.79 - $8.32
($6.8)
$ 3.29-52%New holding, 10237 sh.10,237
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

EXEL is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
EXEL Jean-Marie Eveillard 2013-12-311,173,3000.640.02
Premium Most recent portfolio changes are included for Premium Members only!


EXEL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
WILLSEY LANCEDirector 2013-08-29Buy10,000$5.15-35.53view
MARCHESI VINCENT TDirector 2012-12-20Buy4,000$4.68-29.06view
MARCHESI VINCENT TDirector 2012-12-19Buy6,000$4.72-29.66view
Schwab GiselaEVP and Chief Medical Officer 2012-12-10Buy25,000$4.39-24.37view
MARCHESI VINCENT TDirector 2012-06-14Sell7,000$5.13-35.28view
RIVERA LUPE MEVP, Operations 2010-12-17Sell29,427$8.5-60.94view
RIVERA LUPE MEVP, Operations 2010-12-15Sell75,000$7.5-55.73view
Schwab GiselaEVP & Chief Medical Officer 2010-12-09Sell4,112$6.5-48.92view
WILLSEY LANCEDirector 2010-09-07Buy36,200$3.6-7.78view
WILLSEY LANCEDirector 2010-08-30Buy71,300$3.184.4view

Press Releases about EXEL :

    Quarterly/Annual Reports about EXEL:

    News about EXEL:

    Articles On GuruFocus.com
    5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
    Exelixis Inc. Reports Operating Results (10-K) Feb 22 2011 
    Exelixis Inc. (EXEL) CFO Frank Karbe buys 16,500 Shares Aug 25 2010 
    Exelixis Inc. Reports Operating Results (10-Q) Aug 05 2010 
    Exelixis Inc. Reports Operating Results (10-Q) May 11 2010 
    Exelixis Announces Second Quarter 2009 Financial Results Jul 30 2009 
    Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs Dec 12 2008 

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Hide